SG11201903737PA - Neutralizing anti-tl1a monoclonal antibodies - Google Patents
Neutralizing anti-tl1a monoclonal antibodiesInfo
- Publication number
- SG11201903737PA SG11201903737PA SG11201903737PA SG11201903737PA SG11201903737PA SG 11201903737P A SG11201903737P A SG 11201903737PA SG 11201903737P A SG11201903737P A SG 11201903737PA SG 11201903737P A SG11201903737P A SG 11201903737PA SG 11201903737P A SG11201903737P A SG 11201903737PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- rule
- applicant
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
1 7 3 0 2 2 Log (AL I irdol 125 100 E 75 r„, 25 • 5C3D11 EC 50 = 1 nM 0 1 Lug obi oia 2 9E12E5 EC 50 =2.4 nM W O 20 18/08 107 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT omit VIII °nolo III m H VIII IIIII 110 Immo oimIE (10) International Publication Number WO 2018/081074 Al (51) International Patent Classification: C07K 14/715 (2006.01) A61K 39/395 (2006.01) C07K 14/525 (2006.01) G01N 33/68 (2006.01) C07K 14/52 (2006.01) C12Q 1/68 (2018.01) CO7K 16/24 (2006.01) (21) International Application Number: PCT/US2017/058019 (22) International Filing Date: 24 October 2017 (24.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,188 26 October 2016 (26.10.2016) US (71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Blvd., Los Angeles, California 90048 (US). (72) Inventors: BILSBOROUGH, Janine; 390 Pellburne Ct., Simi Valley, California 93065 (US). TARGAN, Stephan; 240 22nd St., Santa Monica, California 90402 (US). HEN- KLE, Bradley; #203, 1233 Nth Flores St., West Holly- wood, California 90069 (US). (74) Agent: BRESNAHAN, Matthew J.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES FIG. 5 :Panel A. pane i B (57) : Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohns Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413188P | 2016-10-26 | 2016-10-26 | |
PCT/US2017/058019 WO2018081074A1 (en) | 2016-10-26 | 2017-10-24 | Neutralizing anti-tl1a monoclonal antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903737PA true SG11201903737PA (en) | 2019-05-30 |
Family
ID=61971087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903737PA SG11201903737PA (en) | 2016-10-26 | 2017-10-24 | Neutralizing anti-tl1a monoclonal antibodies |
Country Status (11)
Country | Link |
---|---|
US (4) | US10322174B2 (en) |
EP (1) | EP3532489A4 (en) |
JP (2) | JP7194104B2 (en) |
KR (1) | KR20190082815A (en) |
CN (1) | CN110121509B (en) |
AR (1) | AR109882A1 (en) |
MY (1) | MY191324A (en) |
PH (1) | PH12019500946A1 (en) |
SG (1) | SG11201903737PA (en) |
TW (1) | TWI832808B (en) |
WO (1) | WO2018081074A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
CN105246501B (en) | 2013-03-27 | 2021-01-12 | 雪松-西奈医学中心 | Reduction and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
KR20230003433A (en) | 2016-05-20 | 2023-01-05 | 세다르스-신나이 메디칼 센터 | Diagnosis of inflammatory bowel disease based on genes |
MY191324A (en) | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
MA52366A (en) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | OPTIMIZED ANTI-TL1A ANTIBODIES |
JP2021532060A (en) * | 2018-04-30 | 2021-11-25 | シーダーズ—シナイ メディカル センター | Methods and systems for the selection and treatment of patients with inflammatory disease |
JP2022533956A (en) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ,インク. | Methods, Systems, and Devices for Selecting TL1A Patients |
KR20220103721A (en) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof |
CN116322762A (en) * | 2020-06-26 | 2023-06-23 | 辉瑞公司 | Methods of treating inflammatory bowel disease with TL1A antibodies |
EP4333983A1 (en) * | 2021-05-07 | 2024-03-13 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US20030198640A1 (en) | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
US6599719B2 (en) | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
US20030129189A1 (en) | 1994-11-07 | 2003-07-10 | Guo-Liang Yu | Tumor necrosis factor-gamma |
US6824767B2 (en) | 1994-11-07 | 2004-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
EP0792278B1 (en) | 1994-11-07 | 2007-06-13 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
WO1999045959A1 (en) | 1998-03-13 | 1999-09-16 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU5124500A (en) | 1999-04-30 | 2000-11-17 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
ES2353268T3 (en) | 1999-07-02 | 2011-02-28 | Morphosys Ag | GENERATION OF SPECIFIC UNION ELEMENTS THAT JOIN (POLI) PEPTIDES CODIFIED BY FRAGMENTS OF GENOMIC DNA OR EST. |
US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
US6571638B2 (en) | 2000-06-30 | 2003-06-03 | Sawtek, Inc. | Surface-acoustic-wave pressure sensor and associated methods |
AU2001277857A1 (en) | 2000-07-07 | 2002-01-21 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6824989B1 (en) | 2000-09-01 | 2004-11-30 | Upstate Biotechnology, Inc. | Recombinant monoclonal antibody to phosphotyrosine-containing proteins |
CA2391711A1 (en) | 2001-06-26 | 2002-12-26 | University Of Guelph | Non-radioactive assay of lipopolysaccharide kinases |
RS20050300A (en) * | 2002-10-16 | 2007-08-03 | Euro-Celtique S.A., | Antibodies that bind cell-associated ca 125/0772p and methods of use thereof |
EP1567555A4 (en) * | 2002-11-27 | 2006-06-21 | Biogen Idec Inc | Humanized antibodies against monocyte chemotactic proteins |
US20050101889A1 (en) | 2003-11-06 | 2005-05-12 | Freeman Gary A. | Using chest velocity to process physiological signals to remove chest compression artifacts |
WO2006017173A1 (en) * | 2004-07-10 | 2006-02-16 | Alexion Pharmaceuticals, Inc. | Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
CN101198624B (en) | 2005-05-06 | 2012-10-10 | 津莫吉尼蒂克斯公司 | IL-31 monoclonal antibodies and methods of use |
JP5339901B2 (en) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Treatment and evaluation of inflammatory injury |
US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
CN103172737A (en) * | 2005-06-30 | 2013-06-26 | Abbvie公司 | IL-12/P40 binding proteins |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
MX363905B (en) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Single-chain multivalent binding proteins with effector function. |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
US20100055700A1 (en) | 2007-02-28 | 2010-03-04 | Cedars-Sinai Medical Center | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease |
JP5745854B2 (en) * | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Humanized antibody against TL1A |
CN101469270B (en) | 2007-12-27 | 2012-08-22 | 牛斌 | Industrial continuous plastic cracker |
EP2242762B1 (en) | 2008-01-18 | 2015-12-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
ES2493042T3 (en) | 2008-09-29 | 2014-09-11 | Roche Glycart Ag | Antibodies against human IL-17 and their uses |
EP2411412B1 (en) | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
KR20120089259A (en) | 2009-08-03 | 2012-08-09 | 유니버시티 오브 마이애미 | Method for in vivo expansion of t regulatory cells |
WO2011106707A2 (en) | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
PL2616489T3 (en) | 2010-09-16 | 2017-07-31 | Baliopharm Ag | Anti-hutnfr1 antibody |
US8766034B2 (en) * | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
JO3375B1 (en) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | Human antibodies to human tnf-like ligand 1a (tl1a) |
CA2836898A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
KR102051014B1 (en) | 2011-06-03 | 2019-12-04 | 조마 테크놀로지 리미티드 | Antibodies specific for tgf-beta |
WO2013044298A1 (en) | 2011-09-30 | 2013-04-04 | Cephalon Australia Pty Ltd | Antibodies against tl1a and uses thereof |
EP2941302B1 (en) | 2013-01-02 | 2018-08-01 | Glenmark Pharmaceuticals S.A. | Antibodies that bind to tl1a and their uses |
WO2014160463A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
JP6462599B2 (en) * | 2013-03-15 | 2019-01-30 | シャアメン ユニバーシティ | Epitope of RSV fusion protein and antibody recognizing the epitope |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CA3056647A1 (en) * | 2013-11-13 | 2015-05-21 | Robert ARCH | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
JP6868394B2 (en) | 2014-05-16 | 2021-05-12 | ファイザー・インク | Bispecific antibody |
US10160805B2 (en) | 2014-07-11 | 2018-12-25 | New York University | Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody |
MY191428A (en) | 2014-11-14 | 2022-06-27 | Hoffmann La Roche | Antigen binding molecules comprising a tnf family ligand trimer |
TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
WO2017077715A1 (en) | 2015-11-02 | 2017-05-11 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
CR20180365A (en) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES |
EA039084B1 (en) | 2016-05-09 | 2021-12-01 | Бристол-Майерс Сквибб Компани | Tl1a antibodies and uses thereof |
JP7187436B2 (en) | 2016-07-25 | 2022-12-12 | セファロン インコーポレイテッド | Affinity chromatography wash buffer |
MY191324A (en) | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
MA52366A (en) * | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | OPTIMIZED ANTI-TL1A ANTIBODIES |
-
2017
- 2017-10-24 MY MYPI2019002368A patent/MY191324A/en unknown
- 2017-10-24 SG SG11201903737PA patent/SG11201903737PA/en unknown
- 2017-10-24 CN CN201780080666.4A patent/CN110121509B/en active Active
- 2017-10-24 EP EP17865031.3A patent/EP3532489A4/en active Pending
- 2017-10-24 WO PCT/US2017/058019 patent/WO2018081074A1/en unknown
- 2017-10-24 KR KR1020197015021A patent/KR20190082815A/en not_active Application Discontinuation
- 2017-10-24 JP JP2019521389A patent/JP7194104B2/en active Active
- 2017-10-24 US US15/792,266 patent/US10322174B2/en active Active
- 2017-10-25 AR ARP170102965A patent/AR109882A1/en unknown
- 2017-10-26 TW TW106136987A patent/TWI832808B/en active
-
2019
- 2019-04-15 US US16/384,521 patent/US20190247498A1/en not_active Abandoned
- 2019-04-25 PH PH12019500946A patent/PH12019500946A1/en unknown
-
2020
- 2020-11-23 US US17/102,189 patent/US20210093718A1/en not_active Abandoned
-
2022
- 2022-09-28 JP JP2022155453A patent/JP2023002562A/en active Pending
-
2023
- 2023-03-28 US US18/191,712 patent/US20230381308A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020504076A (en) | 2020-02-06 |
CN110121509B (en) | 2024-05-07 |
KR20190082815A (en) | 2019-07-10 |
PH12019500946A1 (en) | 2019-08-19 |
US20180110855A1 (en) | 2018-04-26 |
TW201829461A (en) | 2018-08-16 |
WO2018081074A1 (en) | 2018-05-03 |
AR109882A1 (en) | 2019-01-30 |
US20230381308A1 (en) | 2023-11-30 |
JP2023002562A (en) | 2023-01-10 |
TWI832808B (en) | 2024-02-21 |
US10322174B2 (en) | 2019-06-18 |
MY191324A (en) | 2022-06-15 |
US20190247498A1 (en) | 2019-08-15 |
EP3532489A4 (en) | 2020-07-08 |
US20210093718A1 (en) | 2021-04-01 |
EP3532489A1 (en) | 2019-09-04 |
CN110121509A (en) | 2019-08-13 |
JP7194104B2 (en) | 2022-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201908940UA (en) | Isoquinolines as inhibitors of hpk1 | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |